scholarly journals Current topics in biotechnology patent law: The written description requirement

2005 ◽  
Vol 11 (4) ◽  
Author(s):  
Benjamin A Adler

Universities and medical research institutions are as interested in securing patent protection for their biotechnological inventions as pharmaceutical and biotechnology companies. Obtaining adequate patent protection by universities and research institutions has been hampered by the 'embryonic' nature of its inventions. This problem is particularly noticeable in the fields of biotechnology and molecular medicine. This paper focuses on recent court cases in US biotechnology patent law and analyses the effects of the legal decisions on the effort by universities and research institutions to secure meaningful legal protection for biotechnological inventions.

Author(s):  
European Commission

AbstractIntroductionThis is the second report pursuant to Article 16c of the Directive 98/44/EC of the European Parliament and of the Council of 6 July 1998 on the legal protection of biotechnological inventions and bears the title “Developments and implications of patent law in the field of biotechnology and genetic engineering” (hereinafter the “second 16c Report”).Its purpose is to set out the key events which have occurred since publication of the first 16c Report, and to comment on two issues identified in the latter: the scope of patents on sequences or partial sequences of genes which have been isolated from the human body; and the patentability of human stem cells and cell lines obtained from them. The Commission’s analysis is based on the Commission staff working paper SEC(2005)943.


Author(s):  
Philip W. Grubb ◽  
Peter R. Thomsen ◽  
Tom Hoxie ◽  
Gordon Wright

This chapter considers the law governing the patentability of biological inventions, including microbiological inventions, recombinant DNA technology, and monoclonal antibody technology. Patent protection for biotechnological inventions is of immense commercial importance. But patent law and practice have been unable to keep up with the rapid scientific progress in this field; issues such as inventive step, sufficiency of disclosure, and permissible breadth of claims have proved troublesome. There has been much litigation of biotech patents and courts have found it difficult in such a rapidly moving field to determine what was the general knowledge of the skilled person at the time that the invention was made. Another problem is the opposition of special interest groups to anything related to genetic engineering, particularly the existence of patents in this area.


2005 ◽  
Vol 2 (5) ◽  
Author(s):  
Niclas Kunczik

AbstractThe phenomenon of “the tragedy of the anticommons”Making decisions in the European Union and transforming them into legal instruments can sometimes become a life-task. Although it took a whole decade to adopt the European Communities “Directive 98/44/EC of the European Parliament and the Council of 6 July 1998 on the legal protection of biotechnological inventions”, the political and legal dispute about ”patents on life” was not settled at all. Some member states – the Netherlands, supported by Italy and Norway – took this issue to the European Court of Justice (ECJ) seeking the annulment of the Directive. The Court dismissed this appeal in 2001. But the discussion about ”patents on life” did not end. Even though it has been a somehow accepted fact that patents on living materials including human DNA are being granted, an even more heated discussion is focusing on the scope of those gene-patents. The question is if it is acceptable to allow the classical scope protection for gene sequences, or if the patent protection should be limited to the specific use disclosed in the patent application (“purpose-bound protection”).


2016 ◽  
Vol 50 (3) ◽  
pp. 132-135
Author(s):  
Jyoti Rattan

ABSTRACT In the knowledge society of 21st century, intellectual property rights (IPRs) are real assets and much more valuable and important than are materialistic assets like house, motor car, and so on. Patents are given for inventions which fulfill few important conditions, such as novelty, inventiveness, industrial application, and written description. Significantly, biotechnological invention involves monopoly over life or living beings or living processes, and morally and ethically these are considered to involve tinkering with life or nature. However, today, biotechnological inventions are patentable because of their benefits and utility to the industry. This article is a humble attempt to examine international and national law and judicial decisions relating to patents and biotechnological inventions from a theoretical perspective. How to cite this article Rattan J. Biotechnological Inventions and Patent Law: National and International Perspective. J Postgrad Med Edu Res 2016;50(3):132-135.


2016 ◽  
Vol 13 (3) ◽  
pp. 177
Author(s):  
Joanna Uchańska

A FEW REMARKS ON THE AXIOLOGY OF COMPETITION LAW AND PATENT LAW: THE ABSOLUTE PATENT PROTECTION OF BIOTECHNOLOGICAL INVENTIONSSummary This paper discusses the important issue of the dependence of patent law on competition law, and their relations. The author carries out a comprehensive analysis of the axiomatic foundations of these two systems. She starts by putting a hypothesis that patent law and competition law are complementary. Both are a remedy for the shortcomings of the market, each in a different, but complementary way acting as tools in a mechanism to stimulate innovation. Subsequently, the paper presents the patent protection of biotechnological inventions, in particular its sensitive aspect, namely the absolute protection of biotechnological inventions. Hence she goes on to discuss various standpoints on the patent protection of biotechnological inventions. In the final part of the article she presents the well-nigh inevitable clash between the absolute protection of biotechnological inventions and the law on protection of competition. The article also shows that competition law is in conflict with the axiological foundations of patent protection, in prejudice to the principle that patent protection is a system envisaged for the benefit of society as a whole and should be established and performed using the principle of proportionality.


2016 ◽  
Author(s):  
Mark Lemley

Trade secret law is a puzzle. Courts and scholars have struggled for over acentury to figure out why we protect trade secrets. The puzzle is not inunderstanding what trade secret law covers; there seems to be widespreadagreement on the basic contours of the law. Nor is the problem that peopleobject to the effects of the law. Rather, the puzzle is a theoretical one:no one can seem to agree where trade secret law comes from or how to fit itinto the broader framework of legal doctrine. Courts, lawyers, scholars,and treatise writers argue over whether trade secrets are a creature ofcontract, of tort, of property, or even of criminal law. None of thesedifferent justifications have proven entirely persuasive. Worse, they havecontributed to inconsistent treatment of the basic elements of a tradesecret cause of action, and uncertainty as to the relationship betweentrade secret laws and other causes of action. Robert Bone has gone so faras to suggest that this theoretical incoherence suggests that there is noneed for trade secret law as a separate doctrine at all.In this article, I suggest that trade secrets can be justified as a form,not of traditional property, but of intellectual property (IP). Theincentive justification for encouraging new inventions is straightforward.Granting legal protection for those new inventions not only encouragestheir creation, but enables an inventor to sell her idea. And while we haveother laws that encourage inventions, notably patent law, trade secrecyoffers some significant advantages for inventors over patent protection.It seems odd, though, for the law to encourage secrets, or to encourageonly those inventions that are kept secret. I argue that, paradoxically,trade secret law is actually designed to encourage disclosure, not secrecy.Without legal protection, companies in certain industries would invest toomuch in keeping secrets. Trade secret law develops as a substitute for thephysical and contractual restrictions those companies would otherwiseimpose in an effort to prevent a competitor from acquiring theirinformation.The puzzle then becomes why the law would require secrecy as an element ofthe cause of action if its goal is to reduce secrecy. I argue that thesecrecy requirement serves a channeling function. Only the developers ofsome kinds of inventions have the option to over-invest in physical secrecyin the absence of legal protection. For products that are inherentlyself-disclosing (the wheel, say, or the paper clip), trying to keep theidea secret is a lost cause. We don't need trade secret law to encouragedisclosure of inherently self-disclosing products - inventors of suchproducts will get patent protection or nothing. But if trade secret lawprevented the use of ideas whether or not they were secret, the resultwould be less, not more, diffusion of valuable information. The secrecyrequirement therefore serves a gatekeeper function, ensuring that the lawencourages disclosure of information that would otherwise be kept secret,while channeling inventors of self-disclosing products to the patentsystem.My argument has a number of implications for trade secret policy. First,the theory works only if we treat trade secrets as an IP right, requiringproof of secrecy as an element of protection. If we give the protection tothings that are public, we defeat the purpose and give windfalls to peoplewho may not be inventors (what we might call "trade secret trolls"). Courtsthat think of trade secret law as a common law tort rather than an IP rightare apt to overlook the secrecy requirement in their zeal to reach "badactors." Second, an IP theory of trade secrets also encourages preemptionof "unjust enrichment" theories and other common-law ways courts aretempted to give private parties legal control over information in thepublic domain. Thus, an IP theory of trade secrets is in part a "negative"one: the value of trade secret law lies in part in defining the boundariesof the cause of action and preempting others that might reach too far.Finally, treating trade secrets as IP rights helps secure their place inthe pantheon of legal protection for inventions. The traditional conceptionof the tradeoff between patents and trade secrets views the disclosurefunction of the patent system as one of its great advantages over tradesecret law. And indeed the law operates in various ways to encourageinventors to choose patent over trade secret protection where both arepossible. But for certain types of inventions we may actually get moreuseful "disclosure" at less cost from trade secret than from patent law.


2021 ◽  
Vol 29 (2) ◽  
pp. 200-222
Author(s):  
Lu Sudirman ◽  
Hari Sutra Disemadi

The discovery of technology has a huge impact on the economy of a country, so many countries focus on developing technology and apply this technology in their respective countries. Technological inventions must register patent rights to obtain legal protection to avoid losses that will harm inventors, stimulate creativity in creating new technologies and create fair business competition among companies engaged in technology. This normative research aims to compare patent protection in Indonesia, Singapore, and Hong Kong. The benefit of this research is that it can contribute to scientific literature in the field of patent rights, can provide an overview of the form of patent rights arrangements in several countries outside Indonesia, so as to avoid disputes and/or misunderstandings with other countries. The participation of Indonesia, Singapore, and Hong Kong in ratifying the Convention on the World Trade Organization and the agreement on the Trade Aspects of Intellectual Property Rights (TRIPs) obliges these countries to establish regulations on patents in their respective countries. Although the application of patent law in Indonesia, Singapore, and Hong Kong is based on the terms of the TRIPs agreement, the implementation and regulations must have differences. Patent registration in Indonesia, Singapore, and Hong Kong have the same procedure, namely fulfilling the formal requirements, substantive examination, then the announcement stage. The term of patent protection in Indonesia and Singapore is similar, which is 20 years from the date of filing. However, it is different from Hong Kong, namely from the date of filing. In patent disputes, there are two ways of settlement, namely litigation and non-litigation. Patents in Indonesia, Singapore, and Hong Kong have another similarity, namely that they are transferable and can be licensed. The focus of this research is only to compare the application of patent law and not to examine its strengths and weaknesses, so it is considered important to do further research on this matter.


2006 ◽  
Vol 7 (3) ◽  
pp. 279-291 ◽  
Author(s):  
Christoph Ann

Whether patents should be granted on human genes or gene sequences is highly controversial, both ethically and politically; not only in Germany but throughout Europe and in most parts of the world. Proof of this has been the attention created by US biotechnology company Myriad Genetics, which, in 2001, obtained European patents for human gene sequences indicating an increased risk of certain types of cancer. In Germany the Bundestag has recently addressed the issue: the core of a newly introduced provision of the German Patent Statute (PatG) is Paragraph 1a Sec. 4 PatG, which limits the scope of patent protection available for human gene sequences or parts thereof. If the subject of an invention is a human gene sequence, Paragraph 1a Sec. 4 PatG requires disclosure of not only the sequence but also at least one application. Without such disclosure a human gene sequence is not patentable under German Patent Law. This is remarkable, because under the Directive of the European Parliament and the Council on the Legal Protection of Biotechnological Inventions, the so-called Biotechnology Directive of 1998, a piece of European Union legislation, the situation is different.


2018 ◽  
Author(s):  
Andika carsya nafebra

Very rapid technological development, especially in the field of computers resulted in form legal protection not only through patent protection against hardware but also patents on computer programs. Developments in developed countries have a tendency to patent protection that reaches protection against the formulation of algorithms even programming languages as supporting parts of computer programs such as Extensible Markup Language (abbreviated as XML), while in Indonesia, computer programs themselves are not objects of patent protection. Based on this, the author conducted a research in the form of a thesis with the aim to determine whether Extensible markup language can be an object protected by a patent based on Law No. 14 of 2001 concerning Patents in Indonesia in the case of an XML Patent registered in the United States registered with number 5,787,449 which has just become a dispute in the court in the United States between i4i and Microsoft and how it impacts after a verdict has stated that there has been a violation of an XML patent in another country ... The method used in this research is analytical descriptive method with a normative legal approach. the research conducted was library research and supported by field research through interview instruments. A Programming Language such as Extensible Markup Language cannot be an object that is protected by a Patent Law in Indonesia, the only protection for XML is indirectly protected by Patents, namely through the Treaty of the SamaPaten based on Presidential Decree No. 16 of 1996 where patents can be registered for regional protection fellow WIPO member countries. The existence of a computer program with the extensible markup language feature that has violated patents in the United States in relation to Presidential Decree Number 16 of 1997 in Indonesia does not have executorial power as it applies state-limited patents, except that XML has been registered through PCT Patent protection against XML is possible. By considering priority rights which are limited to retroactive conditions when the patent registration is first registered at least in one other country outside Indonesia.


Author(s):  
Олена Штефан

Currently, the development of a modern economy is based on the rapid development of the latest achievements of science and technology, which in turn are the dominant indicators of state development. Globally, economic globalization and trade liberalization are accelerating, leading not only to the international division of labor, the expansion of markets and the corresponding increase in production, but also to an even greater intensification of competition, increasing the need for innovation and their sound legal protection. The principle (doctrine) of equivalence, which the courts apply in the event of patent disputes, is inextricably linked to these processes. The article reveals the essence and specifics of applying the principle of equivalents by studying the specialized literature and conducting comparative legal analysis of foreign jurisprudence.Despite the fact that the principle of equivalence has attracted the attention of many experts in the field of patent law, however, no criteria and approaches have been developed to put it into practice. An analysis of the literature indicates that researchers focus their attention on determining the principle of equivalence.As a result of the analysis of doctrinal approaches to determining the principle of equivalence, it is concluded that at the legislative level there is no differentiation of features (elements), but there is an indication of the identity of the feature as equivalent. Therefore, the substitution of the characteristic (element) indicated in the claims by the equivalent may be recognized as equivalent from the technical point of view and not from the legal position. Usually, the principle (doctrine) of equivalents is applied after the grant of the patent, and the possibility of assigning features (elements) to equivalents can be evaluated by the real technical means that appeared after the grant of the patent.The principle of equivalents or the doctrine of equivalents is a legal doctrine that was developed in the United States of America in 1850-1860 to counteract imitation, substitution of minor or minor components of a patented invention, while maintaining its other essential identity, to avoid liability.In Germany, the courts have widely used the principle of equivalents in interpreting the formula when dealing with patent infringement cases. In England, the doctrine of equivalents was not used, and the traditional British approach to determining the scope of protection was to interpret the claims literally. The analysis of the jurisprudence of foreign countries on the application of the principle of equivalence in the resolution of patent disputes allows us to draw the following conclusions: the application of the principle of equivalence in resolving the question of the scope of patent protection of inventions strikes a balance between the fair protection of the exclusive rights of the patentee and a certain variation of the elements of the claims by third parties, which will not infringe the patent rights of the patent owners; in determining the limits of patent protection by interpreting the claims, the German courts resort to the principle of equivalence when the claims contain ambiguous restrictions such as numerical ranges; in English courts, patent  infringement and patent jurisdiction issues are dealt with in a single trial, whereby judges' reasoning in the prior art has a greater influence on the understanding of the claims, in contrast to German courts that exclusively deal with patent infringement rights without touching on the aspects of the patent power.The analysis of the Ukrainian legislation has led to the conclusion that the understanding of the principle of equivalence coincides with a literal interpretation of the claims, while the new application of a known  product or process is not foreseen, since the scope of legal protection of such inventions is exhausted only by their formula, and equivalent features are not taken into account.


Sign in / Sign up

Export Citation Format

Share Document